The combination of Upfront’s unique disposable chromatography system and DSM’s proprietary manufacturing technology will reportedly deliver a flexible, easy-to-use and high-capacity bioprocessing platform that can be scaled from 0.1L to 100L for commercial manufacture and recovery of a range of biopharmaceuticals, including monoclonal antibodies.
Michael Bennett, CEO of Upfront said: “The biopharmaceutical industry has been seeking fully disposable chromatography systems over recent years. Our technology offers manufacturers all the productivity benefits they expect from industrial-scale chromatography systems and with DSM Biologics we have the perfect partner to drive this combination of disposable systems and high-yield cell lines to market.”